Exploring the role of a multidisciplinary hereditary gynecologic oncology clinic in epithelial ovarian cancer risk‐reducing surgical decision‐making practices: A mixed‐methods study

• Published in: Journal of genetic counseling Vol. 32; no. 3; pp. 728 - 743
• Main Authors: Casalino, Selina, Bruce, Sharon, Serfas, Kim, Altman, Alon D., Kean, Sarah, Lambert, Pascal, McManus, Kirk J., Hartley, Jessica N., Nachtigal, Mark W.
• Format: Journal Article
• Language: English
• Published: United States Blackwell Publishing Ltd 01-06-2023
• Subjects: Biological organs; BRCA; BRCA1 protein; BRCA2 protein; Breast cancer; Breast Neoplasms - genetics; Carcinoma, Ovarian Epithelial - genetics; Decision making; Fallopian tubes; Female; Genes, BRCA1; Genes, BRCA2; Genetic counseling; Genital Neoplasms, Female - genetics; Gynecology; Health education; Humans; Interdisciplinary aspects; Interviews; Life experiences; lived experience; Marital status; Medical diagnosis; Menopause; Metabolism; Mixed methods research; Mutation; Nurses; Oncologists; Oncology; Oophorectomy; Ovarian cancer; Ovarian Neoplasms - genetics; Ovariectomy; Polls & surveys; Reproductive organs; risk‐reducing surgery; Specialists; Surgery; Surveys; Teams; Variants; Worry; genetic counseling; BRCA; risk-reducing surgery; decision-making; ovarian cancer; lived experience
• ISSN: 1059-7700; 1573-3599
• DOI: 10.1002/jgc4.1684

Individuals that have gynecologic reproductive organs with pathogenic variants in BRCA1 or BRCA2 (“BRCA‐positive”) have an increased risk of developing high‐grade serous ovarian cancer (HGSOC). The majority of HGSOC develops in the fallopian tubes and later spreads to the ovaries and peritoneal cavity. Therefore, risk‐reducing salpingo‐oophorectomy (RRSO) is recommended for those who are BRCA‐positive to preventatively remove their ovaries and fallopian tubes. The Hereditary Gynecology Clinic (HGC) is a provincial program in Winnipeg, Canada, that specifically targets care to the unique needs of such individuals through an interdisciplinary team of gynecological oncologists, menopause specialists, and registered nurses. A mixed‐methods study design was used to explore the decision‐making processes of these BRCA‐positive individuals who have been recommended (or who completed) RRSO and experiences with healthcare providers at the HGC influenced this decision. Individuals who are BRCA‐positive without a previous diagnosis of HGSOC and who had previously received genetic counselling were recruited from the HGC and the provincial cancer genetics program (Shared Health Program of Genetics & Metabolism). Forty‐three people completed a survey and 15 participated in an in‐depth interview about their experiences and decisions surrounding RRSO. Surveys were analyzed to compare scores on validated scales related to decision‐making and cancer‐related worry. Qualitative interviews were transcribed, coded, and analyzed using interpretive description. Participants described the complex decisions faced by those who are BRCA‐positive, which are intertwined with life experiences and circumstances including age, marital status, and family disease history. Participants interpreted their HGSOC risk through a personalized “lens” of contextual factors that impacted perceptions about the practical and emotional implications of RRSO and the need for surgery. Mean scores on validated scales evaluating the HGC's impact on decisional outcomes and preparedness for decision‐making about RRSO were not significant, indicating that the HGC played a supportive role, rather than helping with decision‐making itself. Therefore, we present a novel framework that consolidates the various influences on decision‐making and connects them to the psychological and practical implications of RRSO in the context of the HGC. Strategies for improving support, decisional outcomes, and the overall experiences of individuals who are BRCA‐positive attending the HGC are also described.